

STANDARD MEDICARE PART B MANAGEMENT

ULTOMIRIS (ravulizumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- A. Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
- B. Treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
- C. Ultomiris is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Limitations of Use:

Ultomiris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

All other indications will be assessed on an individual basis. Submissions for indications other than those enumerated in this policy should be accompanied by supporting evidence from Medicare approved compendia.

II. DOCUMENTATION

The following documentation must be available, upon request, for all submissions:

- A. For initial requests:
 1. Paroxysmal nocturnal hemoglobinuria: flow cytometry used to show results of glycosylphosphatidylinositol-anchored proteins (GPI-APs) deficiency
 2. Generalized myasthenia gravis: anti-acetylcholine receptor (AChR) antibody positive, clinical classification of myasthenia gravis score, MG activities of daily living score
- B. For continuation requests: Chart notes or medical record documentation supporting benefit from therapy.

III. CRITERIA FOR INITIAL APPROVAL

A. Paroxysmal Nocturnal Hemoglobinuria (PNH)

Authorization of 6 months may be granted for treatment of paroxysmal nocturnal hemoglobinuria (PNH) when all of the following criteria are met:

1. The diagnosis of PNH was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) as demonstrated by either of the following:

- i. At least 5% PNH cells
 - ii. At least 51% of GPI-AP deficient poly-morphonuclear cells
2. Flow cytometry is used to demonstrate GPI-APs deficiency

B. Atypical hemolytic uremic syndrome (aHUS)

Authorization of 6 months may be granted for treatment of atypical hemolytic uremic syndrome (aHUS) that is not caused by Shiga toxin.

C. Generalized myasthenia gravis (gMG)

Authorization of 6 months may be granted for treatment of generalized myasthenia gravis (gMG) when all of the following criteria are met:

1. Anti-acetylcholine receptor (AChR) antibody positive
2. Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV
3. MG activities of daily living (MG-ADL) total score ≥ 6

IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

A. Paroxysmal Nocturnal Hemoglobinuria (PNH)

Authorization for 12 months may be granted when all of the following criteria are met:

1. The member is currently receiving therapy with Ultomiris
2. The member is receiving benefit from therapy (e.g., improvement in hemoglobin levels, normalization of lactate dehydrogenase [LDH] levels)

B. Atypical hemolytic uremic syndrome (aHUS)

Authorization for 12 months may be granted when all of the following criteria are met:

1. The member is currently receiving therapy with Ultomiris
2. The member is receiving benefit from therapy (e.g., normalization of lactate dehydrogenase [LDH] levels, platelet counts)

C. Generalized myasthenia gravis (gMG)

Authorization for 12 months may be granted when all of the following criteria are met:

1. The member is currently receiving therapy with Ultomiris
2. The member is receiving benefit from therapy (e.g., improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis (QMG) total score)

V. DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

VI. SUMMARY OF EVIDENCE

The contents of this policy were created after examining the following resources:

1. The prescribing information for Ultomiris.

2. The available compendium
 - a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - b. Micromedex DrugDex
 - c. American Hospital Formulary Service- Drug Information (AHFS-DI)
 - d. Lexi-Drugs
 - e. Clinical Pharmacology
3. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy.
4. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry.
5. International consensus guidance for management of myasthenia gravis

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Ultomiris are covered.

VII. EXPLANATION OF RATIONALE

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

Support for using percentage of PNH cells or percentage of GPI-AP deficiency poly-morphonuclear cells can be found in the guidelines for diagnosis of PNH (Borowitz et al and Preis et al). Flow cytometry is the gold standard for assessing the percentage of GPI-AP deficient poly-morphonuclear cells. Classic PNH is defined as greater than 50% of GPI-AP deficient PMNs. It is also possible to diagnose PNH by assessing the percentage of PNH cells. Most clinical trials for the complement inhibitors required at least 10% PNH cells, but the trials associated with Ultomiris only required 5% PNH cells. Therefore, the baseline requirement for all complement inhibitor programs will be at least 5%.

VIII. REFERENCES

1. Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; April 2022.
2. Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. *Hematology*. 2011; 21-29.
3. Lee JW, Sicre de Fontbrune F, Wong LL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. *Blood*. 2019;133(6):530-539. doi:10.1182/blood-2018-09-876136.
4. Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. *Cytometry B Clin Cytom*. 2010; 78: 211-230.
5. Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):208-216.
6. Sanders D, Wolfe G, Benatar M et al. International consensus guidance for management of myasthenia gravis. *Neurology*. 2021; 96 (3) 114-122.
7. Tuan Vu, Andreas Meisel, Renato Mantegazza, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. *NEJM Evid* 2022; 1 (5).